The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 5/117 - Tetrapeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
Sloan-Kettering Institute for Cancer Research (USA)
Inventor
Rafii, Shahin
Zhang, Fan
Seandel, Marco
Abstract
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
The present invention relates to a system for production of ATP. This system is comprised of a support and one or more enzymes coupled to that support which are capable of collectively producing ATP from glucose or fructose metabolism. The present invention is additionally directed to a device, which includes the system, and to a method for carrying out a reaction involving the conversion of ATP to ADP using the system.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
6.
Materials and methods for respiratory disease control in canines
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
CORNELL RESEARCH FOUNDATION, INC. (USA)
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (USA)
Inventor
Crawford, Patti Cynthia
Gibbs, Paul J.
Dubovi, Edward J.
Donis, Ruben Omar
Katz, Jacqueline
Klimov, Alexander I.
Lakshmanan, Nallakannu P.
Lum, Melissa Anne
Goovaerts, Daniel Ghislena Emiel
Mellencamp, Mark William
Cox, Nancy J.
Castleman, William L.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Sloan-Kettering Institute for Cancer Research (USA)
Inventor
Rafii, Shahin
Zhang, Fan
Seandel, Marco
Abstract
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
The present invention relates to a system for production of ATP. This system is comprised of a support and one or more enzymes coupled to that support which are capable of collectively producing ATP from glucose or fructose metabolism. The present invention is additionally directed to a device, which includes the system, and to a method for carrying out a reaction involving the conversion of ATP to ADP using the system.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
10.
Structured finance securities option pricing architecture and process
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
CORNELL RESEARCH FOUNDATION, INC. (USA)
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (USA)
Inventor
Crawford, Patti Cynthia
Gibbs, Paul J.
Dubovi, Edward J.
Donis, Ruben Omar
Katz, Jacqueline
Klimov, Alexander I.
Lakshmanan, Nallakannu P.
Lum, Melissa Anne
Goovaerts, Daniel Ghislena Emiel
Mellencamp, Mark William
Cox, Nancy J.
Castleman, William L.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Sloan-Kettering Institute for Cancer Research (USA)
Inventor
Rafii, Shahin
Zhang, Fan
Seandel, Marco
Abstract
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
CORNELL RESEARCH FOUNDATION, INC. (USA)
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEAS CONTROL AND PREVENTION (USA)
Inventor
Crawford, Patti Cynthia
Gibbs, Paul J.
Dubovi, Edward J.
Donis, Ruben Omar
Katz, Jacqueline
Klimov, Alexander I.
Lakshmanan, Nallakannu P.
Lum, Melissa Anne
Goovaerts, Daniel Ghislena Emiel
Mellencamp, Mark William
Cox, Nancy J.
Castleman, William L.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A method for assessing risk of losing a transplanted organ by a patient having an episode of acute rejection of the transplanted organ is described. The method includes obtaining from the patient a cell sample from the transplanted organ or peripheral blood, determining a level of FOXP3 in the cell sample, and correlating the level with the risk of loss of the transplanted organ, wherein, compared to a control level, a significantly greater level of FOXP3 in the cell sample from the transplanted organ or a significantly lower level of FOXP3 in the cell sample from the peripheral blood correlates with a decreased risk of loss of the transplanted organ.
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C08G 64/34 - General preparatory processes using carbon dioxide and cyclic ethers
C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyltransferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
CORNELL RESEARCH FOUNDATION, INC. (USA)
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION (USA)
Inventor
Crawford, Patti Cynthia
Gibbs, Paul J.
Dubovi, Edward J.
Donis, Ruben Omar
Katz, Jacqueline
Klimov, Alexander I.
Lakshmanan, Nallakannu P.
Lum, Melissa Anne
Goovaerts, Daniel Ghislena Emiel
Mellencamp, Mark William
Cox, Nancy J.
Castleman, William L.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Catalysts and methods for the double carbonylation of epoxides are disclosed. Each epoxide molecule reacts with two molecules of carbon monoxide to produce a succinic anhydride. The reaction is facilitated by catalysts combining a Lewis acidic species with a transition metal carbonyl complex. The double carbonylation is achieved in single process by using reaction conditions under which both carbonylation reactions occur without the necessity of isolating or purifying the product of the first carbonylation.
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 5/117 - Tetrapeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
Sloan-Kettering Institute for Cancer Research (USA)
Inventor
Rafii, Shahin
Zhang, Fan
Seandel, Marco
Abstract
The present invention relates to adenovirus E4ORF1 gene and to endothelial cells engineered to express the E4ORF1 gene. The present invention also relates to uses of the E4ORF1 gene, and cells expressing the E4ORF1 gene, and to compositions comprising the E4ORF1 gene, or comprising cells expressing the E4ORF1 gene.
Sloan-Kettering Institute for Cancer Research (USA)
Cornell Research Foundation, Inc. (USA)
Inventor
Tan, Derek Shieh
Quadri, Luis E. N.
Ryu, Jae-Sang
Cisar, Justin Scott
Ferreras, Julian Alberto
Lu, Xuequan
Abstract
Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
C07H 19/24 - Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof
Catalysts and methods for the double carbonylation of epoxides are disclosed. Each epoxide molecule reacts with two molecules of carbon monoxide to produce a succinic anhydride. The reaction is facilitated by catalysts combining a Lewis acidic species with a transition metal carbonyl complex. The double carbonylation is achieved in single process by using reaction conditions under which both carbonylation reactions occur without the necessity of isolating or purifying the product of the first carbonylation.
The invention relates to methods of preventing or inhibiting the onset and/or treating autoimmune demyelinating neuropathy and other autoimmune or inflammatory diseases involving macrophage infiltration.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
26.
System and method to enable training a machine learning network in the presence of weak or absent training exemplars
Described is a system and method for training a machine learning network. The method comprises initializing at least one of nodes in a machine learning network and connections between the nodes to a predetermined strength value, wherein the nodes represent factors determining an output of the network, providing a first set of questions to a plurality of users, the first set of questions relating to at least one of the factors, receiving at least one of choices and guesstimates from the users in response to the first set of questions and adjusting the predetermined strength value as a function of the choices/guesstimates. The real and simulated examples presented demonstrate that synthetic training sets derived from expert or non-expert human guesstimates can replace or augment training data sets comprised of actual training exemplars that are too limited in size, scope, or quality to otherwise generate accurate predictions.
G06E 1/00 - Devices for processing exclusively digital data
G06E 3/00 - Devices not provided for in group , e.g. for processing analogue or hybrid data
G06F 15/18 - in which a program is changed according to experience gained by the computer itself during a complete run; Learning machines (adaptive control systems G05B 13/00;artificial intelligence G06N)
G06G 7/00 - Devices in which the computing operation is performed by varying electric or magnetic quantities
Disclosed is an isolated nucleic acid molecule comprising a nucleotide sequence that is at least 90% identical to a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO 4, wherein the protein has an aspartic acid (Asp) at amino acid position 106 Transgenic plants compπsing the nucleic acid have reduced or delayed softening and detenoration of fruit compared to wild-type plants Methods of genetic screening for plants having reduced or delayed softening and detenoration of fruit, isolated oligonucleotides, and a method of imparting to a plant the dfd trait are also disclosed.
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
Inventor
Mitchum, Melissa, G.
Replogle, Amy
Wang, Jianying
Wang, Xiaohong
Chen, Shiyan
Lang, Ping
Davis, Eric, L.
Baum, Thomas, J.
Hussey, Richard, S.
Abstract
Methods of inhibiting plant parasitic nematodes, methods of obtaining transgenic plants useful for inhibiting such nematodes, and transgenic plants that are resistant to plant parasitic nematodes through inhibition of plant nematode CLE peptide receptor genes are provided. Methods for expressing genes at plant parasitic nematode feeding sites with plant nematode CLE peptide receptor gene promoters are also provided, along with nematode CLE peptide receptor gene promoters that are useful for expressing genes in nematode feeding sites as well as transgenic plants and nematode resistant transgenic plants comprising the promoters.
An illumination system is disclosed for use in non-linear modulation transfer microscopy and micro-spectroscopy. The illumination system includes a laser system for providing a first train of pulses at a center optical frequency ω1, and an optical assembly for collinearly combining a first train of pulses with a second train of pulses having a center optical frequency of ω2 as synchronized excitation fields for non¬ linear modulation transfer microscopy and micro-spectroscopy. The laser system includes a continuous wave laser for providing a first continuous wave field, a first chirp modulator system comprising a means to receive the first continuous wave field, a means to receive a trigger signal, a first phase modulator and a first electro-optic modulator; and a first pulse compression unit.
University of Florida Research Foundation, Inc. (USA)
The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention (USA)
Cornell Research Foundation, Inc. (USA)
Inventor
Crawford, Patti C.
Gibbs, Paul J.
Dubovi, Edward J.
Donis, Ruben Omar
Katz, Jacqueline
Klimov, Alexander I.
Lakshmanan, Nallakannu P.
Lum, Melissa Anne
Goovaerts, Daniel Ghislena Emiel
Mellencamp, Mark William
Castleman, William L.
Cox, Nancy J.
Abstract
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
31.
SYSTEM AND METHODS FOR MAPPING AND SEARCHING OBJECTS IN MULTIDIMENSIONAL SPACE
This invention relates to a system and methods for determining the placement of an object in a distributed key-value store by mapping the object to nodes in multidimensional hyperspace. A search function supports efficient object retrieval, even when the search query requests multiple objects and specifies them through non-primary keys. In response to a search query, the search is translated into hyperregions in the hyperspace to determine the set of nodes that hold the queried data object. The number of contacted nodes and the number of scanned objects are significantly reduced in comparison to prior art techniques.
High aspect ratio micromachined structures in semiconductors are used to improve power density in Betavoltaic cells by providing large surface areas in a small volume. A radioactive beta-emitting material may be placed within gaps between the structures to provide fuel for a cell. The pillars may be formed of SiC. In one embodiment, SiC pillars are formed of n-type SiC. P type dopant, such as boron is obtained by annealing a borosilicate glass boron source formed on the SiC. The glass is then removed. In further embodiments, a dopant may be implanted, coated by glass, and then annealed. The doping results in shallow planar junctions in SiC.
The present invention relates to a system for production of ATP. This system is comprised of a support and one or more enzymes coupled to that support which are capable of collectively producing ATP from glucose or fructose metabolism. The present invention is additionally directed to a device, which includes the system, and to a method for carrying out a reaction involving the conversion of ATP to ADP using the system.
C12P 19/32 - Nucleotides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same-ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyl-transferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.
C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
A subdural electro-optical sensor system may include a substrate to which is attached an array of electrodes, light emitters, and light detectors. The sensor system may be sufficiently thin, flexible, sterile and biocompatible to be positioned subdurally.
The present invention relates to a method of identifying a protein that binds to a target molecule and has intracellular functionality. This method includes providing a construct comprising a deoxyribonucleic acid molecule encoding the protein which binds to the target molecule, with the deoxyribonucleic acid molecule being coupled to a stall sequence. A host cell is transformed with the construct and then cultured under conditions effective to form, within the host cell, a complex of the protein whose translation has been stalled, the mRNA encoding the protein, and ribosomes. The protein in the complex is in a properly folded, active form and the complex is recovered from the cell.
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
A microelectromechanical structure (MEMS) device includes a secondary MEMS element displaceably coupled to a substrate. A primary MEMS element is displaceably coupled to the secondary MEMS element and has a resonant frequency substantially equal to the secondary MEMS element and has a much larger displacement than the secondary MEMS element.
G01P 15/08 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values
39.
E. COLI LPFA ANTIGEN FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES
The present disclosure relates to methods and compositions for the treatment and prevention of microbial infections and for the enhancement of resistance to infection. The disclosure includes administration of an effective amount of an E. coli LpfA antigen to enhance the immune system to prevent infections that cause, e.g., inflammatory bowel diseases, bovine mastitis and metritis. The disclosure also includes methods for diagnosing microbial infection and conditions associated with microbial infection by detecting an E. coli LpfA polypeptide or nucleic acid.
The present invention relates to evaluating the effect of physiological conditions on the occurrence of ventricular fibrillation, identifying strategies for treatment or prevention of ventricular fibrillation or ventricular tachycardia, and evaluating a subject for induction of ventricular fibrillation from a condition of ventricular tachycardia.
The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed.
C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
43.
METHODS AND KITS FOR DIAGNOSIS OF CANCER AND PREDICTION OF THERAPEUTIC VALUE
A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.
A self-powered sensor (e.g., 100, 180, 220, 400) can wake-up systems requiring a trigger signal to wake-up circuits or systems in power-sleep mode, conserving the battery power for emergency computations and communications. In a humidity sensor embodiment 100, radioisotope generated voltage biases are employed to power sensor capacitors to realize self-powered sensors. A first self-powered capacitor biasing architecture 160 is based on changes in the leakage resistance of the polymer capacitor 110, and a second self-powered capacitor biasing architecture 140 uses changes in the capacitance of the polymer capacitor. Another sensor embodiment uses changes in the capacitance or leakage resistance of the sensor capacitor to modulate conductance of a MOSFET 114, realizing an easily readable electronic output signal. A temperature sensor embodiment 180 and a MEMS cantilever structure based fissile material proximity sensor embodiment 400 are also disclosed.
Mycobacterium tuberculosis by administering rhodanine derivatives of formula (I), as well as some novel such compounds. Other embodiments are also disclosed.
A device is provided for sensing an electrocardiogram signal of a patient. The device includes a substrate and a plurality of electrodes mounted to the substrate. The plurality of electrodes are configured to sense an electrocardiogram signal of a patient when the plurality of electrodes are placed in contact with the patient. The device may include a strap configured to wrap around a portion of the patient wherein the substrate mounts to the strap. The device further may include a respiration sensor mounted to the strap.
A nanofluidic channel fabricated in fused silica with an approximately 500 nm square cross section was used to isolate, detect and identify individual quantum dot conjugates. The channel enables the rapid detection of every fluorescent entity in solution. A laser of selected wavelength was used to excite multiple species of quantum dots and organic molecules, and the emission spectra were resolved without significant signal rejection. Quantum dots were then conjugated with organic molecules and detected to demonstrate efficient multicolor detection. PCH was used to analyze coincident detection and to characterize the degree of binding. The use of a small fluidic channel to detect quantum dots as fluorescent labels was shown to be an efficient technique for multiplexed single molecule studies. Detection of single molecule binding events has a variety of applications including high throughput immunoassays.
Sloan Kettering Institute for Cancer Research (USA)
Rutgers, The State University of New Jersey (USA)
Inventor
Barany, Francis
Cheng, Yu-Wei
Paty, Philip
Notterman, Daniel
Abstract
The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
50.
Production of optical pulses at a desired wavelength using soliton self-frequency shift
The present invention relates to an apparatus for producing optical pulses of a desired wavelength. The apparatus includes an optical pulse source operable to generate input optical pulses at a first wavelength. The apparatus further includes a higher order mode (HOM) fiber module operable to receive the input optical pulses at the first wavelength, and thereafter to produce output optical pulses at the desired wavelength by soliton self-frequency shift (SSFS). The present invention also relates to a method of producing optical pulses having a desired wavelength. This method includes generating input optical pulses using an optical pulse source, where the input optical pulses have a first wavelength and a first spatial mode. The input optical pulses are delivered into an HOM fiber module to alter the wavelength of the input optical pulses from the first wavelength to a desired wavelength by soliton self-frequency shift (SSFS) within the HOM fiber module, thereby producing output optical pulses having the desired wavelength.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
An optical modulator includes a ring resonator with a waveguide adjacent to and optically coupled to the micro-ring resonator. A p-i-n junction is formed about the ring resonator. An optional additional doped region may be formed opposite the waveguide from the ring resonator and when combined with the p-i-n junction forms a nearly closed p-i-n junction about the ring resonator. The ring resonator may be a silicon micro-ring resonator. Multiple different resonant frequency resonators may be coupled to the waveguide along with different detectors to multiplex light on the waveguide. The spectrum of the resonator may be controlled by an applied voltage. A prepulsing device may be used to enhance electrical transitions to enhance the speed of the modulator.
G02F 1/035 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on ceramics or electro-optical crystals, e.g. exhibiting Pockels or Kerr effect in an optical waveguide structure
52.
Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
Sloan-Kettering Institute for Cancer Research (USA)
Inventor
Rafii, Shahin
Zhang, Fan
Seandel, Marco
Abstract
The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
53.
Production of optical pulses at a desired wavelength using soliton self-frequency shift in higher-order-mode fiber
The present invention relates to an apparatus for producing optical pulses of a desired wavelength. The apparatus includes an optical pulse source operable to generate input optical pulses at a first wavelength. The apparatus further includes a higher-order-mode (HOM) fiber module operable to receive the input optical pulses at the first wavelength, and thereafter to produce output optical pulses at the desired wavelength by soliton self-frequency shift (SSFS). The present invention also relates to a method of producing optical pulses having a desired wavelength. This method includes generating input optical pulses using an optical pulse source, where the input optical pulses have a first wavelength and a first spatial mode. The input optical pulses are delivered into an HOM fiber module to alter the wavelength of the input optical pulses from the first wavelength to a desired wavelength by soliton self-frequency shift (SSFS) within the HOM fiber module, thereby producing output optical pulses having the desired wavelength.
G02B 6/42 - Coupling light guides with opto-electronic elements
H01S 3/30 - Lasers, i.e. devices using stimulated emission of electromagnetic radiation in the infrared, visible or ultraviolet wave range using scattering effects, e.g. stimulated Brillouin or Raman effects
H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
The invention provides variant phytase enzymes having increased thermal stability relative to their counterpart parent enzymes. The modifications to the enzymes include both single substitutions and various combinations of substitutions that provide improved stability and activity. The invention further provides nucleic acids encoding the variant phytase enzymes, host cells and vectors containing and expressing them, as well as feed compositions useful for providing improved nutrition, particularly with respect to the bioavailability of dietary phosphate, calcium, iron and zinc, among others.
The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
56.
Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
The present invention relates to a method of preventing or treating a disease caused by infection by a eukaryotic pathogen, wherein the method comprises administering an effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of a eukaryotic pathogen's adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of a eukaryotic pathogen's adenylyl cyclase that do not substantially modulate an adenylyl cyclase of the subject. The invention also provides methods for culturing eukaryotic pathogens and methods for inducing the pathogenic state in vitro.
Federacion Nacional de Cafeteros de Colombia (Colombia)
Inventor
Rose, Jocelyn
Zornosa, Ricardo Acuna
Abstract
The present invention relates to an isolated β-mannanase protein having an amino acid sequence which is 90% similar to the amino acid sequence of SEQ ID NO: 1, as well as isolated polynucleotides encoding the β-mannanase protein, and isolated expression systems and host cells containing the polynucleotides. The present invention also relates to a method of recombinantly producing β-mannanase protein. Also disclosed is a method of degrading mannans and polysaccharides in plant material, which involves providing plant material and contacting the plant material with the β-mannanase protein of the present invention under conditions effective to degrade mannans and polysaccharides in the plant material.
C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
58.
INORGANIC BULK MULTIJUNCTION MATERIALS AND PROCESSES FOR PREPARING THE SAME
A nanostructured composite material comprising semiconductor nanocrystals in a crystalline semiconductor matrix. Suitable nanocrystals include silicon, germanium, and silicon-germanium alloys, and lead salts such as PbS, PbSe, and PbTe. Suitable crystalline semiconductor matrix materials include Si and silicon-germanium alloys. A process for making the nanostructured composite materials. Devices comprising nanostructured composite materials.
H01L 31/0384 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their crystalline structure or particular orientation of the crystalline planes including other non-monocrystalline materials, e.g. semiconductor particles embedded in an insulating material
The present invention provides a generalizable single-source sol-gel precursor capable of introducing a wide range of functionalities to metal oxides such as silica. The sol-gel precursor facilitates a one-molecule, one-step approach to the synthesis of metal-silica hybrids with combinations of biological, catalytic, magnetic, and optical functionalities. The single-source precursor also provides a flexible route for simultaneously incorporating functional species of many different types. The ligands employed for functionalizing the metal oxides are derived from a library of amino acids, hydroxy acids, or peptides and a silicon alkoxide, allowing many biological functionalities to be built into silica hybrids. The ligands can coordinate with a wide range of metals via a carboxylic acid, thereby allowing direct incorporation of inorganic functionalities from across the periodic table. Using the single-source precursor a wide range of functionalized nanostructures such as monolith structures, mesostructures, multiple metal gradient mesostructures and Stober-type nanoparticles can be synthesized.
H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Calcium-phosphate nanofiber matrices comprising randomly dispersed crystalline calcium-phosphate nanofibers are provided. The nanofibers are synthesized using sol-gel methods combined with electrospinning. The nanofibers may be hollow, solid or may comprise a calcium-phosphate shell surrounding a polymer containing inner core to which biologically functional additives may be added. The nanofiber matrices may be used to culture bone and dental cells, and as implants to treat bone, dental or periodontal diseases and defects.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
Heterocycles, e.g., epoxides, are carbonylated at low pressure with high percentage conversion to cyclic, ring expanded products using the catalyst
where L is tetrahydrofuran (THF).
The present invention discloses transgenic plants having an altered level of NAP protein compared to that of a non-transgenic plant, where the transgenic plants display an altered leaf senescence phenotype relative to a non-transgenic plant, as well as mutant plants comprising an inactivated NAP gene, where mutant plants display a delayed leaf senescence phenotype compared to that of a non-mutant plant. The present invention also discloses methods for delaying leaf senescence in a plant, as well as methods of making a mutant plant having a decreased level of NAP protein compared to that of a non-mutant plant, where the mutant plant displays a delayed leaf senescence phenotype relative to a non-mutant plant. Methods for causing precocious leaf senescence or promoting leaf senescence in a plant are also disclosed. Also disclosed are methods of identifying a candidate plant suitable for breeding that displays a delayed leaf senescence and/or enhanced yield phenotype.
The present invention relates to the microRNA miR-126 and to inhibitors of miR- 126 that regulate angiogenesis. The present invention provides compositions and methods for the inhibition of miR-126 and for the inhibition of angiogenesis in vivo.
Provided is a method for treatment and/or prophylaxis of FIP in cats. The method is performed by administering to a cat a composition comprising a therapeutic and/or prophylactic amount of a cysteine protease inhibitor. The cysteine protease inhibitor can be a selective cathepsin B inhibitor. Also provided is a method for inhibiting FIPV replication. The method comprises contacting a cell infected with FIPV with a cysteine protease inhibitor in an amount effective to inhibit replication of FIPV. It is expected the method will be effective for therapy or prophylaxis of FIP in any species of cat and will be effective against any strain of feline coronavirus.
This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition comprising conjugated linoleic acids (CLAs), cis-9, trans-11 and trans-10, cis-12. When these CLAs are fed daily to dairy cows starting at or prior to calving, and continued after parturition, an improvement in reproductive performance is observed.
A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
67.
METHOD FOR PROPHYLAXIS AND TREATMENT OF EQUINE HERPESVIRUS TYPE 1 INFECTIONS
Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs.
The present invention relates to a nucleic acid aptamer having a first domain that binds to a fluorescent protein. The nucleic acid aptamer forms a molecular complex whereby the aptamer binds a fluorescent protein at the first domain. A constructed DNA molecule, expression systems, and host cells containing the molecular complex are also disclosed. The invention also relates to a system containing a first DNA molecule encoding the nucleic acid aptamer of the present invention and a second DNA molecule encoding a fluorescent protein capable of being bound by the first domain. Methods of detecting a molecular target and determining location of a molecular target using the nucleic acid aptamer of the invention are also disclosed.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
69.
Event-synchronization protocol for parallel simulation of large-scale wireless networks
An event synchronization protocol called time-based synchronization (TBS) is employed to control operation of a network simulation. In TBS, processors in the simulated network execute events based on comparisons between timestamps for each event and a value generated by a time tracking device in the processor. In this manner, event execution is not dependent on other processes in the network and the simulation can actually be carried out at speeds faster than real time. A multiprocessor network is specially designed to execute TBS-based simulations.
The invention relates to a prokaryotic host cell comprising eukaryotic glycosyttransferase activity, wherein the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GIcNAc transferase activity and eukaryotic mannosyltransferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the disclosure pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format. A glycosylated antibody comprising an Fv portion which recognizes and binds to a native antigen and an Fc portion which is glycosylated at a conserved asparagine residue is also disclosed.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
71.
SELF-POWERED LITHOGRAPHY METHOD AND APPARATUS USING RADIOACTIVE THIN FILMS
A self-powered 'near field' lithographic system 100 includes three primary components, namely, a thin film or emitter substrate 110 including a radioactive material (e.g., a radioisotope 112), a target substrate 120 which carries an energy-modifiable layer 122 (e.g., photo-resist) and a stencil (e.g., 130) that is either positioned between the emitter and target substrates fabricated upon and defined in the emitter substrate. The stencil is made from a material capable of blocking particles emitted through radioactive decay from the radioisotope of the emitter substrate. The stencil includes openings or vias 132 patterned to permit selective transmission of the particles emitted through radioactive decay from the radioisotope of the emitter substrate 110, and the stencil is preferably placed up against (or very close to) the target substrate 120.
Sloan-Kettering Institute for Cancer Research (USA)
Cornell Research Foundation, Inc. (USA)
Inventor
Tan, Derek Shieh
Quadri, Luis E. N.
Ryu, Jae-Sang
Cisar, Justin Scott
Ferreras, Julian Alberto
Lu, Xuequan
Abstract
Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
An array of electrochemical detectors includes an array of electrodes that provide current responsive to oxidation events. Each electrode is coupled to a transistor, an amplifier coupled to an input of the transistor and having a feedback loop coupled to the electrode and providing a bias voltage to the electrode, an integrating capacitor coupled to the transistor operable to integrate charge from the electrode, and a reset switch coupled to the integrating capacitor. The amplifier may have a shared stage with other detectors. A shared buffer circuit may also provide a sampled output from multiple detectors.
G01N 27/49 - Systems involving the determination of the current at a single specific value, or small range of values, of applied voltage for producing selective measurement of one or more particular ionic species
G01N 33/487 - Physical analysis of biological material of liquid biological material
The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
Federacion Nacional de Cafeteros de Colombia (Colombia)
Inventor
Rose, Jocelyn
Acuña, Ricardo
Abstract
The present invention relates to an isolated β-mannanase protein having an amino acid sequence which is 90% similar to the amino acid sequence of SEQ ID NO:1, as well as isolated polynucleotides encoding the β-mannanase protein, and isolated expression systems and host cells containing the polynucleotides. The present invention also relates to a method of recombinantly producing β-mannanase protein. Also disclosed is a method of degrading mannans and polysaccharides in plant material, which involves providing plant material and contacting the plant material with the β-mannanase protein of the present invention under conditions effective to degrade mannans and polysaccharides in the plant material.
A nanofluidic channel fabricated in fused silica with an approximately 500 nm square cross section was used to isolate, detect and identify individual quantum dot conjugates. The channel enables the rapid detection of every fluorescent entity in solution. A laser of selected wavelength was used to excite multiple species of quantum dots and organic molecules, and the emission spectra were resolved without significant signal rejection. Quantum dots were then conjugated with organic molecules and detected to demonstrate efficient multicolor detection. PCH was used to analyze coincident detection and to characterize the degree of binding. The use of a small fluidic channel to detect quantum dots as fluorescent labels was shown to be an efficient technique for multiplexed single molecule studies. Detection of single molecule binding events has a variety of applications including high throughput immunoassays.
Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
The present invention relates to a system for production of ATP. This system is comprised of a support and one or more enzymes coupled to that support which are capable of collectively producing ATP from glucose or fructose metabolism. The present invention is additionally directed to a device, which includes the system, and to a method for carrying out a reaction involving the conversion of ATP to ADP using the system.
A cellular antioxidant activity (CAA) assay for quantifying the antioxidant activity of phytochemicals, food extracts, and dietary supplements has been developed. Dichlorofluorescin is a probe that is trapped within cells and is easily oxidized to fluorescent dichlorofluorescein (DCF). The method measures the ability of compounds to prevent the formation of DCF by 2,2'-azobis(2-amidinopropane) dihydrochloride (ABAP)-generated peroxyl radicals in human hepatocarcinoma HepG2 cells. The decrease in cellular fluorescence when compared to the control cells indicates the antioxidant capacity of the compounds. The antioxidant activities of selected phytochemicals and fruit extracts were evaluated using the CAA assay and the results were expressed in 쎽-mol quercetin equivalents/100 쎽-mol phytochemical or 쎽-mol quercetin equivalents/100 g fresh fruit. Quercetin had the highest CAA value, followed by kaempferol, epigallocatechin gallate (EGCG), myricetin, and luteolin among the pure compounds tested. Among the selected fruits tested, blueberry had the highest CAA value, followed by cranberry ᡶ apple = red grape ᡶ green grape. The CAA assay is a more biologically relevant method than the popular chemistry antioxidant activity assays because it accounts for aspects of uptake, metabolism, and location of species within cells.
G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
80.
METHODS TO IMPROVE ALCOHOL TOLERANCE OF MICROORGANISMS
The present invention is directed to a method of producing organisms tolerant to alcohol, that includes selecting a microorganism needing tolerance to alcohol and modifying the selected microorganism under conditions effective to overproduce inositol by the microorganism compared to when the microorganism is not modified, with the modified microorganism being tolerant to alcohol. The present invention is also directed to a method of producing alcohol that includes providing a microorganism tolerant to alcohol which is modified to overproduce inositol by the microorganism compared to when the microorganism is not modified. A fermentable feedstock is treated with the modified microorganism under conditions effective to produce the alcohol. The modified microorganism is also able to produce and tolerate alcohol in high osmolarity feedstocks.
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
81.
METHOD AND SYSTEM FOR EFFICIENT AND EXPRESSIVE ADVERTISING AUCTIONS
A system and method for allowing advertisers to express bids as bidding programs that take as input, for example, a search query and various statistics about auction history and performance, for outputting bids on output characteristics such as, for example, clicks, purchases, and slot positions, and for providing an efficient, scalable, and parallelizable algorithm to solve winner determination given the bids output by the bidding programs.
Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drdl COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention.
C08G 63/66 - Polyesters containing oxygen in the form of ether groups
C08F 16/12 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical by an ether radical
84.
PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER
The present invention relates to proteasome inhibitors and their use in methods of treating a subject for a pathogen infection or cancer. The methods involve administering to the subject a compound of Formula (I). (I) where: Q is Formula or Formula, where the crossing dashed line illustrates the bond formed joining Q to the rest of the compound of Formula (I). The remainder of substituents of the compound of Formula (I) are defined in the present application.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
The present invention provides novel bimetallic complexes and methods of using the same in the isoselective polymerization of epoxides. The invention also provides methods of kinetic resolution of epoxides. The invention further provides polyethers with high enantiomeric excess that are useful in applications ranging from consumer goods to materials.
C07D 301/06 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with air or molecular oxygen in the liquid phase
C07D 303/04 - Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
C08G 59/68 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups characterised by the catalysts used
C08G 65/10 - Saturated oxiranes characterised by the catalysts used
B01J 31/04 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
The invention relates to detection and/or monitoring of inflammatory neuropathy using markers that specifically indicate the presence of inflammatory neuropathy, for example, allograft inflammatory factor 1 (AIF1), lymphatic hyaluronan receptor (LYVE-1), FYN binding protein (FYB), myeloid/lymphoid or mixed-lineage leukemia, translocated to, 3 (MLLT3), purinergic receptor P2Y, G-protein coupled, 1 (P2RY1) or a combination thereof. According to the invention, skin biopsies can be used for assessing the expression of these markers.
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (USA)
CORNELL RESEARCH FOUNDATION, INC. (USA)
Inventor
Marambaud, Philippe
Campagne, Fabien
Abstract
Provided are methods of determining the likelihood that a subject will be diagnosed with Alzheimer's disease. Also provided are isolated and purified mammalian CALHM I, CALHM2, and CALHM3 proteins, vectors comprising a nucleic acid sequence encoding the CALHM 1, CALHM2, and CALHM3 proteins, and mammalian cells transfected with the vectors. Additionally, methods of affecting Ca2+ levels in a mammalian cell are provided. Further provided are methods of screening a test compound for the ability to alter calcium homeostasis in mammalian cells. Also, methods of affecting Ca2+ levels in mammalian cells are provided. Additionally provided are methods of screen ing a test compound for the ability to inhibit ERK I/2 phosphorylation in a mammalian cell. Further provided are methods of screening a test compound for the ability to inhibit amyloid-beta peptide accumulation in a mammalian cell or biological fluid. Also provided are methods of screening for a test compound that may affect Alzheimer's disease.
The present invention relates to a device and methods for detecting or quantifying an analyte in a test sample. The device includes a substrate defining one or more microchannels and having a reaction region in a first portion of the one or more microchannels, wherein the reaction region contains a first binding element selected to bind with a first portion of the analyte. The device also includes a detection region in fluid communication with the reaction region. The detection region includes a second binding element selected to immobilize the analyte within the detection region. Methods of detecting or quantifying an analyte in a test sample using the device of the present invention are also disclosed. A method for coating a polymer with a gold layer is also disclosed.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
89.
PROTEIN DISCOVERY USING INTRACELLULAR RIBOSOME DISPLAY
The present invention relates to a method of identifying a protein that binds to a target molecule and has intracellular functionality. This method includes providing a construct comprising a deoxyribonucleic acid molecule encoding the protein which binds to the target molecule, with the deoxyribonucleic acid molecule being coupled to a stall sequence. A host cell is transformed with the construct and then cultured under conditions effective to form, within the host cell, a complex of the protein whose translation has been stalled, the mRNA encoding the protein, and ribosomes. The protein in the complex is in a properly folded, active form and the complex is recovered from the cell. This method can be carried out with a cell-free extract preparation containing ribosomes instead of a host cell. The present invention also relates to a construct which includes a deoxyribonucleic acid molecule encoding a protein that binds to a target molecule and an SecM stalling sequence coupled to the deoxyribonucleic acid molecule. The deoxyribonucleic acid molecule and the SecM stalling sequence are coupled with sufficient distance between them to permit expression of their encoded protein, within the cell, in a properly folded, active form.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
The United States of America as Represented by the Secretary of Agriculture (USA)
Inventor
Lei, Xingen
Mullaney, Edward J.
Ullah, Abul
Abstract
The present invention relates to an isolated nucleic acid molecule encoding a mutant phytase and the isolated mutant phytase itself. The present invention further relates to methods of using the isolated nucleic acid molecule and the isolated mutant phytase of the present invention.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A system and method for enabling distributed transaction processing by moving all application logic away from the server and into the client by using an optimistic concurrency control framework with client-side transaction validation including virtual full replication under a transactional programming model with full Atomicity, Consistency, Isolation, and Durability (ACID) properties.
G06F 15/16 - Combinations of two or more digital computers each having at least an arithmetic unit, a program unit and a register, e.g. for a simultaneous processing of several programs
G06F 17/00 - Digital computing or data processing equipment or methods, specially adapted for specific functions
92.
THE USE OF PLANT GLYCOSYL HYDROLASES WITH CARBOHYDRATE BINDING MODULES TO ALTER PLANT CELL WALL COMPOSITION AND STRUCTURE, OR ENHANCE DEGRADATION
The present invention discloses a transgenic plant cell which includes a nucleic acid construct. The nucleic acid construct contains a nucleic acid molecule encoding a plant endo-l,4-β-xylanase and/or a plant endo-l,4-β- glucanase, where the plant endo-l,4-β-xylanase and/or the plant endo-l,4-β- glucanase each have a modular carbohydrate binding domain, or multiple modular carbohydrate binding domains. The nucleic acid construct also includes a plant promoter and a plant termination sequence, where the plant promoter and the plant termination sequence are operably coupled to the nucleic acid molecule and at least one of the plant promoter or the plant termination sequence is heterologous to the nucleic acid molecule. The present invention also relates to methods of producing transgenic plants, polysaccharide depolymerizing the transgenic plants and non-transgenic plants, and identifying plants capable of undergoing enhanced polysaccharide depolymerization.
The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed.
A sensor system utilizing flexible electronics for on-line real-time high-sensitivity sampling, monitoring, and analysis of a parameter or analyte of interest in a fluid or in or on a solid is provided. The flexible substrate sensor system comprises a plurality of sensors, a flexible substrate, a network, and a connection between the sensors and the network, wherein the network reads out or collects information from the sensors. The network can be onboard, connected by via a physical connection to the sensors and the flexible substrate, or external to the sensors and flexible substrate, connected via a telemetric or wireless connection to the sensors. The flexible substrate sensor system can be deployed in systems that conduct or distribute fluids or solids, such as distribution systems (municipal water systems, oil or gas pipeline systems), industrial systems (production facilities, piping, and storage systems), and large structures (dams, bridges, walkways, buildings).
A method is provided for producing an arthropod comprising introducing a microsystem such as a MEMS device into an immature arthropod under conditions that result in producing an adult arthropod with a functional microsystem permanently attached to its body. A method is also provided for producing a robotic apparatus. The method can comprise introducing a microsystem such as a MEMS device into an immature arthropod under conditions that result in producing a robotic apparatus with the microsystem permanently attached to the body of the adult arthropod.
A subdural electro-optical sensor system may include a substrate to which is attached an array of electrodes, light emitters, and light detectors. The sensor system may be sufficiently thin, flexible, sterile and biocompatible to be positioned subdurally.
The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof.
The invention is directed to a microcapsule containing a catalyst. The invention also provides a system for making and using these microcapsules. The inventive microcapsules may be hollow and, further, may encapsulate a solution. Moreover, the catalyst may be soluble in the encapsulated solution. The semi-permeable shell of the microcapsule allows reactants to diffuse into the interior of the microcapsule and react with the catalyst to form a product which may diffuse out of the microcapsule. Using such a system, one pot multi-step reactions can be conducted in the presence of incompatible catalysts, incompatible reagents, and/or incompatible microenvironments.
To avoid harmful nonlinear effects in the amplification of short optical pulses, an initial pulse is divided into a sequence of lower-energy temporally spaced pulses that are otherwise identical to the original pulse. The low-intensity pulses are amplified and then recombined to create a final amplified output pulse.
The present invention provides non-compressible and/or non-swelling particles comprising a material conjugated to catalyst, microreactors comprising a packed tube containing these inventive particles, methods of making these inventive particles, and methods of using microreactors comprising a packed tube containing these inventive particles. The particles may be re-useable.
patents
